Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBA University of Colorado professor has won the 2024 Alton Ochsner Award Relating Smoking and Disease for his work into how genetic and environmental factors, including smoking, contribute to a person’s risk of idiopathic pulmonary fibrosis (IPF) — when the disease is due to unknown causes.
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with …
Study reveals potential to reverse lung fibrosis using the body's …
WEBApr 12, 2024 · Researchers are urgently trying to find ways to prevent or slow idiopathic pulmonary fibrosis (IPF) and related lung conditions, which can cause worsening shortness of breath, dry cough, and...
New prototype therapy may repair IPF lung scarring by …
WEBApr 26, 2024 · Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports.
New study offers hope for pulmonary fibrosis patients - Medical …
WEBSep 30, 2023 · Using a new recipe for growing blood vessels from living lung tissue in the lab, a University of Virginia School of Engineering and Applied Science research team has developed an analytical tool...
Experimental anticancer drug shows promise as treatment for …
WEBAug 23, 2022 · An experimental anticancer drug called saracatinib shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), a chronic and often fatal condition that causes scarring or fibrosis of the lungs and makes breathing difficult.
Researchers identify new molecular target for idiopathic …
WEBMar 10, 2021 · Researchers have identified a new molecular target that could lead to new treatments for idiopathic pulmonary fibrosis (IPF), a deadly lung disease. IPF is characterized by severe scarring of the lungs, a condition called fibrosis, which makes it progressively difficult to breathe.
Nerandomilast Shows Promise in Idiopathic Pulmonary Fibrosis Trial
WEBSep 17, 2024 · Top-line results were announced from a phase 3 trial evaluating nerandomilast an oral, investigational phosphodiesterase 4B inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry …
Fighting fibrosis - Nature Biotechnology
WEBAug 1, 2022 · Two recent sets of positive clinical data have bucked the trend in the failure-strewn idiopathic pulmonary fibrosis (IPF) field: Boehringer Ingelheim’s phase 2 data for phosphodiesterase 4B...
Study reveals potential to reverse lung fibrosis using the body's …
WEBApr 12, 2024 · Researchers are urgently trying to find ways to prevent or slow idiopathic pulmonary fibrosis (IPF) and related lung conditions, which can cause worsening shortness of breath, dry cough, and...
- Some results have been removed